Name:	SB 202026
Other Names:	Memric, Sabcomeline
Development Status:	investigational in U.S.
FDA Phase:	Discontinued
Primary Medical Role:	Reduce AD symptoms.
Role in Alzheimer's Disease:	Reduce symptoms in mild/moderate Alzheimer.
Pharmacological Role:	Selective muscarinic m1 partial agonist (m1 receptors localized mostly to hippocampus and frontal cortex).
Side Effects:	Relative to placebo group (25 ug bid vs. placebo): insomnia (9.1 % vs. 2.2%), anxiety (5.7% vs. 1.1%), diarrhea(4.5% vs. 1.1%).
Evidence pro its efficacy:	In short-term randomized, placebo-controlled, double- blinded studies, this medication appears to improve cognitive symptoms relative to placebo.
Evidence con its efficacy:	Longer-term studies are necessary, both for concerns of efficacy and toxicity.
Dosage:	25 ug bid
Notes:	Testing discontinued after Phase II clinical trial.

References

Hatcher JP, Loudon JM, Hagan JJ, Clark MS. Sabcomeline (SB- 202026), a functionally selective M1 receptor partial agonist, reverses delay-induced deficits in the T-maze. Psychopharmacology (Berl). 1998 Aug;138(3-4):275-82. Abstract

Harries MH, Samson NA, Cilia J, Hunter AJ. Related The profile of sabcomeline (SB-202026), a functionally selective M1 receptor partial agonist, in the marmoset. Br J Pharmacol. 1998 May;124(2):409-15. Abstract

Bromidge SM, Brown F, Cassidy F, Clark MS, Dabbs S, Hadley MS, Hawkins J, Loudon JM, Naylor CB, Orlek BS, Riley GJ. Design of [R-(Z)]-(+)-alpha-(methoxyimino)-1-azabicyclo [2.2.2]octane-3-acetonitri le (SB 202026), a functionally selective azabicyclic muscarinic M1 agonist incorporating the N-methoxy imidoyl nitrile group as a novel ester bioisostere. J Med Chem. 1997 Dec 19;40(26):4265-80. Abstract

Loudon JM, Bromidge SM, Brown F, Clark MS, Hatcher JP, Hawkins J, Riley GJ, Noy G, Orlek BS. SB 202026: a novel muscarinic partial agonist with functional selectivity for M1 receptors. J Pharmacol Exp Ther. 1997 Dec;283(3):1059- 68. Abstract